Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × veltuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Lymphoma, B-Cell 2 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 133 Dexamethasone 112 Rituximab 73 fludarabine 64 Lenalidomide 58 Cytarabine 58 Gemcitabine 55 Bortezomib 50 fludarabine phosphate 48 pembrolizumab 46 venetoclax 45 Etoposide 45 Paclitaxel 44 Carboplatin 43 Cisplatin 42 pomalidomide 38 Peripheral Blood Stem Cell Transplantation 37 Filgrastim 37 Radiotherapy 36 Bevacizumab 33 Melphalan 31 carfilzomib 30 Calcium Dobesilate 30 Busulfan 30 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 25 Oxaliplatin 24 Nivolumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡